{"success":true,"data":{"pressRelease":{"id":"14018","rtpr_id":"nBw4LrD1ja","ticker":"IBRX","exchange":"NASDAQ","all_tickers":["IBRX"],"title":"Robbins LLP Urges IBRX Stockholders to Contact the Firm for Information About the Class Action Against ImmunityBio, Inc.","author":"Business Wire","published_at":"2026-04-29T22:57:00.115Z","article_body":"Robbins LLP Urges IBRX Stockholders to Contact the Firm for Information About\nthe Class Action Against ImmunityBio, Inc.\n\nRobbins LLP\n(https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Frobbinsllp.com%2Fimmunitybio-inc-2%2F&esheet=54525806&newsitemid=20260429763777&lan=en-US&anchor=Robbins+LLP&index=1&md5=4d6f7709cb4ab98edb338f2d81ee5c6b)\nreminds stockholders that a class action was filed on behalf of all investors\nwho purchased or otherwise acquired ImmunityBio, Inc. (NASDAQ: IBRX)\nsecurities between January 19, 2026 and March 25, 2026. ImmunityBio is a\nbiotechnology company and ANKTIVA is the Company's lead biologic product.\n\nFor more information, submit a form\n(https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Frobbinsllp.com%2Fimmunitybio-inc-2%2F&esheet=54525806&newsitemid=20260429763777&lan=en-US&anchor=form&index=2&md5=4b957571a2621ecc717a150f7bd9210f)\n, email (mailto:adumas@robbinsllp.com) attorney Aaron Dumas, Jr., or give us a\ncall at (800) 350-6003.\n\nWhat is the class period? January 19, 2026 – March 25, 2026\n\nWhat are the allegations? Robbins LLP is Investigating Allegations that\nImmunityBio, Inc. (IBRX) Misled Investors Regarding its Lead Product Candidate\n\nAccording to the complaint, during the class period, defendant Soon-Shiong\nmaterially overstated Anktiva’s capabilities.\n\nPlaintiff alleges that on March 24, 2026, a warning letter from the U.S. Food\nand Drug Administration regarding defendant Soon-Shiong's claims about Anktiva\nwas publicized. The warning letter indicated that \"the promotional\ncommunications create a misleading impression that Anktiva, a treatment for\ncertain type of bladder cancer, can cure and even prevent all cancer.\" The\nletter articulated additional false claims made by Soon-Shiong. On this news,\nImmunityBio common stock fell $1.98 per share, or 21%, to close at $7.42 per\nshare on March 24, 2026.\n\nWhat can shareholders do now? You may be eligible to participate in the class\naction against ImmunityBio, Inc. Shareholders who wish to serve as lead\nplaintiff for the class must submit their papers to the court by May 26, 2026.\nThe lead plaintiff is a representative party who acts on behalf of other class\nmembers in directing the litigation. You do not have to participate in the\ncase to be eligible for a recovery. If you choose to take no action, you can\nremain an absent class member. For more information, click here\n(https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Frobbinsllp.com%2Fimmunitybio-inc-2%2F&esheet=54525806&newsitemid=20260429763777&lan=en-US&anchor=here&index=3&md5=9d0f3dd419f8f2c1fd19a0ac9fea0590)\n.\n\nAll representation is on a contingency fee basis. Shareholders pay no fees or\nexpenses.\n\nAbout Robbins LLP: A recognized leader in shareholder rights litigation, the\nattorneys and staff of Robbins LLP\n(https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Frobbinsllp.com%2F&esheet=54525806&newsitemid=20260429763777&lan=en-US&anchor=Robbins+LLP&index=4&md5=354b62b197cc40760983a9b30652ffee)\nhave been dedicated to helping shareholders recover losses, improve corporate\ngovernance structures, and hold company executives accountable for their\nwrongdoing since 2002.\n\nTo be notified if a class action against ImmunityBio, Inc. settles or to\nreceive free alerts when corporate executives engage in wrongdoing, sign up\nfor Stock Watch\n(https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Frobbinsllp.com%2Fstock-watch%2F&esheet=54525806&newsitemid=20260429763777&lan=en-US&anchor=Stock+Watch&index=5&md5=5b977c901a163f334727a85df461d9d1)\ntoday.\n\nAttorney Advertising. Past results do not guarantee a similar outcome.\n\n\n\nView source version on businesswire.com:\nhttps://www.businesswire.com/news/home/20260429763777/en/\n(https://www.businesswire.com/news/home/20260429763777/en/)\n\nAaron Dumas, Jr.\n\nRobbins LLP\n\n5060 Shoreham Pl., Ste. 300\n\nSan Diego, CA 92122\n\nadumas@robbinsllp.com \n(mailto:adumas@robbinsllp.com) \n(800) 350-6003\n\nwww.robbinsllp.com\n(https://cts.businesswire.com/ct/CT?id=smartlink&url=http%3A%2F%2Fwww.robbinsllp.com&esheet=54525806&newsitemid=20260429763777&lan=en-US&anchor=www.robbinsllp.com&index=6&md5=4de2dd89fa5aec44e60455ec793b914d)\n\n\nCopyright Business Wire 2026","article_body_html":"","raw_payload":{"data":{"id":"nBw4LrD1ja","title":"Robbins LLP Urges IBRX Stockholders to Contact the Firm for Information About the Class Action Against ImmunityBio, Inc.","author":"Business Wire","ticker":"IBRX","created":"2026-04-29T22:57:00.115Z","tickers":["IBRX"],"exchange":"NASDAQ","article_body":"Robbins LLP Urges IBRX Stockholders to Contact the Firm for Information About\nthe Class Action Against ImmunityBio, Inc.\n\nRobbins LLP\n(https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Frobbinsllp.com%2Fimmunitybio-inc-2%2F&esheet=54525806&newsitemid=20260429763777&lan=en-US&anchor=Robbins+LLP&index=1&md5=4d6f7709cb4ab98edb338f2d81ee5c6b)\nreminds stockholders that a class action was filed on behalf of all investors\nwho purchased or otherwise acquired ImmunityBio, Inc. (NASDAQ: IBRX)\nsecurities between January 19, 2026 and March 25, 2026. ImmunityBio is a\nbiotechnology company and ANKTIVA is the Company's lead biologic product.\n\nFor more information, submit a form\n(https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Frobbinsllp.com%2Fimmunitybio-inc-2%2F&esheet=54525806&newsitemid=20260429763777&lan=en-US&anchor=form&index=2&md5=4b957571a2621ecc717a150f7bd9210f)\n, email (mailto:adumas@robbinsllp.com) attorney Aaron Dumas, Jr., or give us a\ncall at (800) 350-6003.\n\nWhat is the class period? January 19, 2026 – March 25, 2026\n\nWhat are the allegations? Robbins LLP is Investigating Allegations that\nImmunityBio, Inc. (IBRX) Misled Investors Regarding its Lead Product Candidate\n\nAccording to the complaint, during the class period, defendant Soon-Shiong\nmaterially overstated Anktiva’s capabilities.\n\nPlaintiff alleges that on March 24, 2026, a warning letter from the U.S. Food\nand Drug Administration regarding defendant Soon-Shiong's claims about Anktiva\nwas publicized. The warning letter indicated that \"the promotional\ncommunications create a misleading impression that Anktiva, a treatment for\ncertain type of bladder cancer, can cure and even prevent all cancer.\" The\nletter articulated additional false claims made by Soon-Shiong. On this news,\nImmunityBio common stock fell $1.98 per share, or 21%, to close at $7.42 per\nshare on March 24, 2026.\n\nWhat can shareholders do now? You may be eligible to participate in the class\naction against ImmunityBio, Inc. Shareholders who wish to serve as lead\nplaintiff for the class must submit their papers to the court by May 26, 2026.\nThe lead plaintiff is a representative party who acts on behalf of other class\nmembers in directing the litigation. You do not have to participate in the\ncase to be eligible for a recovery. If you choose to take no action, you can\nremain an absent class member. For more information, click here\n(https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Frobbinsllp.com%2Fimmunitybio-inc-2%2F&esheet=54525806&newsitemid=20260429763777&lan=en-US&anchor=here&index=3&md5=9d0f3dd419f8f2c1fd19a0ac9fea0590)\n.\n\nAll representation is on a contingency fee basis. Shareholders pay no fees or\nexpenses.\n\nAbout Robbins LLP: A recognized leader in shareholder rights litigation, the\nattorneys and staff of Robbins LLP\n(https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Frobbinsllp.com%2F&esheet=54525806&newsitemid=20260429763777&lan=en-US&anchor=Robbins+LLP&index=4&md5=354b62b197cc40760983a9b30652ffee)\nhave been dedicated to helping shareholders recover losses, improve corporate\ngovernance structures, and hold company executives accountable for their\nwrongdoing since 2002.\n\nTo be notified if a class action against ImmunityBio, Inc. settles or to\nreceive free alerts when corporate executives engage in wrongdoing, sign up\nfor Stock Watch\n(https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Frobbinsllp.com%2Fstock-watch%2F&esheet=54525806&newsitemid=20260429763777&lan=en-US&anchor=Stock+Watch&index=5&md5=5b977c901a163f334727a85df461d9d1)\ntoday.\n\nAttorney Advertising. Past results do not guarantee a similar outcome.\n\n\n\nView source version on businesswire.com:\nhttps://www.businesswire.com/news/home/20260429763777/en/\n(https://www.businesswire.com/news/home/20260429763777/en/)\n\nAaron Dumas, Jr.\n\nRobbins LLP\n\n5060 Shoreham Pl., Ste. 300\n\nSan Diego, CA 92122\n\nadumas@robbinsllp.com \n(mailto:adumas@robbinsllp.com) \n(800) 350-6003\n\nwww.robbinsllp.com\n(https://cts.businesswire.com/ct/CT?id=smartlink&url=http%3A%2F%2Fwww.robbinsllp.com&esheet=54525806&newsitemid=20260429763777&lan=en-US&anchor=www.robbinsllp.com&index=6&md5=4de2dd89fa5aec44e60455ec793b914d)\n\n\nCopyright Business Wire 2026"},"type":"article","timestamp":"2026-04-29T22:57:00.148155526Z","server_sent_at_ms":1777503420148},"received_at":"2026-04-29T22:57:00.202Z","source_url":"https://www.businesswire.com/news/home/20260429763777/en/"},"analysis":{"id":"10903","press_release_id":"14018","analysis_json":{"industry":{"label":"Pharmaceuticals, Biotechnology & Life Sciences","sector":"Health Care"},"redFlags":["class action lawsuit filed alleging misrepresentation of lead product capabilities","FDA warning letter cited regarding misleading promotional claims","stock dropped 21% on March 24 following news of FDA letter"],"eventType":"legal_litigation","narrative":"Robbins LLP announced a class action lawsuit against ImmunityBio for investors who purchased securities between January 19 and March 25, 2026.\n\nThe lawsuit alleges that the company materially overstated the capabilities of its lead product Anktiva, leading to a 21% stock drop after an FDA warning letter was publicized.\n\nShareholders have until May 26, 2026, to seek lead plaintiff status in the litigation.","sentiment":"bearish","agentHooks":{"shouldPost":true,"suggestedAngle":"Class action alleges CEO overstated Anktiva's efficacy, triggering FDA warning and steep share price decline."},"keyFigures":{},"quotedText":"the promotional communications create a misleading impression that Anktiva, a treatment for certain type of bladder cancer, can cure and even prevent all cancer","namedEntities":{"people":[{"name":"Soon-Shiong","role":"Defendant / CEO"},{"name":"Aaron Dumas, Jr.","role":"Attorney"}],"products":["ANKTIVA"],"companies":[{"name":"Robbins LLP","relationship":"plaintiff counsel"},{"name":"ImmunityBio, Inc.","ticker":"IBRX"},{"name":"U.S. Food and Drug Administration","relationship":"regulator"}],"dollarAmounts":[{"amount":"$1.98 per share","context":"stock price drop on March 24, 2026"},{"amount":"21%","context":"percentage stock price drop on March 24, 2026"},{"amount":"$7.42 per share","context":"closing stock price on March 24, 2026"}]},"materialImpact":{"score":4,"reasoning":"A class action lawsuit has been filed alleging material misstatements by the CEO regarding the lead product Anktiva, which triggered a 21% stock drop upon the FDA warning letter's release. This is a significant regulatory and legal overhang."},"tickerRelevance":{"others":[],"primary":"IBRX"},"globalImportance":30,"audienceRelevance":45,"eventTypeSecondary":[],"importanceComponents":{"tickerTier":"mid-cap","eventGravity":"class action / regulatory warning","sectorWeight":"biotech","householdBrandBoost":0,"marketCapAdjustment":0,"retailFavoriteBoost":0}},"event_type":"legal_litigation","event_type_secondary":null,"sentiment":"bearish","material_impact_score":4,"narrative":"Robbins LLP announced a class action lawsuit against ImmunityBio for investors who purchased securities between January 19 and March 25, 2026.\n\nThe lawsuit alleges that the company materially overstated the capabilities of its lead product Anktiva, leading to a 21% stock drop after an FDA warning letter was publicized.\n\nShareholders have until May 26, 2026, to seek lead plaintiff status in the litigation.","key_figures":{},"named_entities":{"people":[{"name":"Soon-Shiong","role":"Defendant / CEO"},{"name":"Aaron Dumas, Jr.","role":"Attorney"}],"products":["ANKTIVA"],"companies":[{"name":"Robbins LLP","relationship":"plaintiff counsel"},{"name":"ImmunityBio, Inc.","ticker":"IBRX"},{"name":"U.S. Food and Drug Administration","relationship":"regulator"}],"dollarAmounts":[{"amount":"$1.98 per share","context":"stock price drop on March 24, 2026"},{"amount":"21%","context":"percentage stock price drop on March 24, 2026"},{"amount":"$7.42 per share","context":"closing stock price on March 24, 2026"}]},"model_name":"glm-4.7","prompt_hash":"sha256:1fc968c3ac7f7ebb","schema_hash":"sha256:1f8af1196c7db48c","created_at":"2026-04-30T01:34:37.850Z","global_importance":30,"audience_relevance":45,"importance_components":{"tickerTier":"mid-cap","eventGravity":"class action / regulatory warning","sectorWeight":"biotech","householdBrandBoost":0,"marketCapAdjustment":0,"retailFavoriteBoost":0}},"durationMs":135944,"modelName":"glm-4.7"}}